Evidence map›Paper›PMID 29563877›Full record

ArticleFrontiers in physiology2018

Soluble Fms-Like Tyrosine Kinase-1 Alters Cellular Metabolism and Mitochondrial Bioenergetics in Preeclampsia.

Lissette C Sánchez-Aranguren, Cindy T Espinosa-González, Laura M González-Ortiz, Sandra M Sanabria-Barrera, Carlos E Riaño-Medina, Andrés F Nuñez, Asif Ahmed, Jeannette Vasquez-Vivar, Marcos López

Open access · goldAbstract read
In one paragraph

Article in Frontiers in physiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Review
  3. Placental Mitochondrial Function and Dysfunction in Preeclampsia.International journal of molecular sciences · 2023
    Review
  4. Article
  5. Article
  6. Oxidative Regulation of Vascular CaAntioxidants (Basel, Switzerland) · 2022
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 4 countries.

Lissette C Sánchez-ArangurenTraslational Biomedical Research Group, Fundación Cardiovascular de Colombia, Santander, Colombia.
Cindy T Espinosa-GonzálezGraduate Program in Biomedical Sciences, Faculty of Health, Universidad del Valle, Cali, Colombia.
Laura M González-OrtizTraslational Biomedical Research Group, Fundación Cardiovascular de Colombia, Santander, Colombia.
Sandra M Sanabria-BarreraTraslational Biomedical Research Group, Fundación Cardiovascular de Colombia, Santander, Colombia.
Carlos E Riaño-MedinaGraduate Program in Biomedical Sciences, Faculty of Health, Universidad del Valle, Cali, Colombia.
Andrés F NuñezMaternal-Fetal Medicine Unit, Clínica Materno Infantil San Luis, Bucaramanga, Santander, Colombia.
Asif AhmedAston Medical Research Institute, Aston Medical School, Aston University, Birmingham, United Kingdom.
Jeannette Vasquez-VivarRedox Biology Program and Free Radical Research Center, Department of Biophysics, Medical College of Wisconsin, Milwaukee, WI, United States.
Marcos LópezTraslational Biomedical Research Group, Fundación Cardiovascular de Colombia, Santander, Colombia.
Universidad del Valle · COAston University · GBFundación Cardiovascular de Colombia · COHospital Universitario Infantil San José · COMedical College of Wisconsin · US

Funding

British Heart Foundation FS/15/72/31676
6 · The paper itself

Abstract

Preeclampsia is a maternal hypertensive disorder that affects up to 1 out of 12 pregnancies worldwide. It is characterized by proteinuria, endothelial dysfunction, and elevated levels of the soluble form of the vascular endothelial growth factor receptor-1 (VEGFR-1, known as sFlt-1). sFlt-1 effects are mediated in part by decreasing VEGF signaling. The direct effects of sFlt-1 on cellular metabolism and bioenergetics in preeclampsia, have not been established. The goal of this study was to evaluate whether sFlt-1 causes mitochondrial dysfunction leading to disruption of normal functioning in endothelial and placental cells in preeclampsia. Endothelial cells (ECs) and first-trimester trophoblast (HTR-8/SVneo) were treated with serum from preeclamptic women rich in sFlt-1 or with the recombinant protein. sFlt-1, dose-dependently inhibited ECs respiration and acidification rates indicating a metabolic phenotype switch enhancing glycolytic flux. HTR-8/SVneo displayed a strong basal glycolytic metabolism, remaining less sensitive to sFlt-1-induced mitochondrial impairment. Moreover, results obtained in ECs exposed to serum from preeclamptic subjects demonstrated that increased sFlt-1 leads to metabolic perturbations accountable for mitochondrial dysfunction observed in preeclampsia. sFlt-1 exacerbated mitochondrial reactive oxygen species (ROS) formation and mitochondrial membrane potential dissipation in ECs and trophoblasts exposed to serum from preeclamptic women. Forcing oxidative metabolism by culturing cells in galactose media, further sensitized cells to sFlt-1. This approach let us establish that sFlt-1 targets mitochondrial function in ECs. Effects of sFlt-1 on HTR-8/SVneo cells metabolism were amplified in galactose, demonstrating that sFlt-1 only target cells that rely mainly on oxidative metabolism. Together, our results establish the early metabolic perturbations induced by sFlt-1 and the resulting endothelial and mitochondrial dysfunction in preeclampsia.

Indexed as

endothelial dysfunctionmetabolismmitochondrial dysfunctionoxidative stress and metabolic perturbationspreeclampsiasFlt-1

Identifiers

PMID29563877
PMCPMC5845757
OpenAlexW2790749276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.